RAS Archives - Immuneering Corporation

immun-ops2020 In Publications

Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results

Presented as an Encore Presentation at the PanCAN Scientific Summit on September 28th, 2025.

Read More

immun-ops2020 In Publications

Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in Ras-Mutant Cancers

Presented at the 7th Annual RAS-Targeted Drug Development Summit in Boston on September 17th, 2025.

Read More

immun-ops2020 In Publications

Potential anti-cachexia properties of novel dual-MEK inhibitor IMM-1-104

Presented at SCWD, December 2024.

Read More

immun-ops2020 In Publications

Phase 1 Interim Population PK/PD Modeling and Recommended Phase 2 Dose Exploration for IMM-1-104, A Novel Concept Oral Deep Cyclic Inhibitor of MEK

Presented at ACoP, Pheonix, AZ, USA (November 13, 2024)

Read More